Amylose AA

Amylose AA

Yilmaz S et al. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever Rheumatology (Oxford). 2015 Mar;54(3):564-5Lire le résumé
Hamanoue S et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016 Jul;26(4):610-3Lire le résumé
Lane T et al.Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2017 Sep;24(3):189–93. Lire le résumé
Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid. 2018 Jan 2;25(1):37–45.Lire le résumé
Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of
secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine. 2017 Aug;96(34):e7859.

Stankovic Stojanovic K, Georgin-Lavialle S, Poitou C, Buob D, Amselem S, Grateau G, et al. AA amyloidosis is an emerging cause of nephropathy in obese patients. European Journal of Internal Medicine. 2017 Apr;39:e18–20.
Lire le résumé

Complément de résumé
Okuda Y,Yamada T, Ueda M, Ando Y. First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Internal Medicine [Internet]. 2019 [cited 2018 Oct 29]; Available from: Lire le résumé
, Calderaro JLetouzé E, Bayard Q, Boulai A, Renault V, Deleuze J-F, et al. Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine. 2018 Sep 20;379(12):1178–80.Lire le résumé
Kisla Ekinci RM, Balci S, Bisgin A, Hershfield M, Atmis B, Dogruel D, et al. Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. Pediatrics. 2018 Nov;142(5):e20180948

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine. 2014 Mar 6;370(10):911–20

Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. The Journal of Rheumatology. 2015 Aug;42(8):1532–4
Lire le résumé
Hong Y, Standing ASI, Nanthapisal S, Sebire N, Jolles S, Omoyinmi E, et al. Autoinflammation due to homozygous S208 MEFV mutation. Annals of the Rheumatic Diseases. 2018 Oct 24;annrheumdis-2018-214102Lire le résumé